Download Free Medical Drug development planning through to late stage challenges PowerPoint Presentation

Drug development planning through to late stage challenges PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Drug Development, which is titled "Drug development planning through to late stage challenges", to know about drug development from planning to late stage challenges.

Tags : Drug Development, planning, challenges

Published on : Jul 20, 2021 | Views : 2048 | Downloads : 4

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Postgraduate Course in Pharmaceutical MedicineSession 1 Helicopter view: Drug development planning through to late stage challenges Madhu Davies January 2018
Slide 2-

Madhu Davies January 2018
Slide 3-

Forbes 4th Jan 2016: 2015 New Drug Approvals Hit 66-Year High! “2015 has been a remarkable year for pharmaceutical innovation. What would have been a dream (or perhaps a delusion) a few years ago has happened. Last year’s new drug approvals reached 51, besting every year since 1950. This tally includes 45 drugs approved by FDA’s Center for Drug Evaluation and Research (CDER), and 6 recombinant therapies approved by the Center for Biologics Evaluation and Research (CBER). The latter include four drugs to treat blood coagulation disorders (e.g., hemophilia), a therapeutic vaccine for melanoma, and a preventive vaccine for meningococcal meningitis type B” Madhu Davies January 2018
Slide 4-

By contrast.... Madhu Davies January 2018
Slide 5-

And then 2017- back up again... (Source Forbes) Madhu Davies January 2018
Slide 6-

What are we here for? "It is not enough to be busy; so are the ants. The question is: What are we busy about?" Henry David Thoreau Madhu Davies January 2018
Slide 7-

Industry overview and R&D structures Development planning theme Madhu Davies January 2018
Slide 8-

What turns C33H34FN2O5 into a blockbuster? C33H34FN2O5 Madhu Davies January 2018
Slide 9-

Madhu Davies January 2018 Strategy
Slide 10-

PGCPM: scope provides a firm foundation Madhu Davies January 2018 R&D structure-pressures and drivers Programme planning; IP/ legal; Statistics and data management; Drug safety/pharmacovigilance; HEOR; Logistics/operations Med education, information and promotion; KOL development
Slide 11-

R&D driving forces Madhu Davies January 2018
Slide 12-

R&D driving forces Pharma productivity stable Attrition rates up Cash: R&D costs up by c16% vs increased sales c12% by 20201 Company size and therapy area split Investor sentiment Global economy Skills/knowledge based economy 1.EvaluatePharma2014 / 17 Reports Madhu Davies January 2018
Slide 13-

Therapy area split- 2013 vs 2020 Madhu Davies January 2018
Slide 14-

Funding and sources of ideas Old world “DIY” Our discovery lab Our scientists Our compound library Our cash (private or shareholders) New world “Collaboration” 1 Open Innovation Sponsored Research Consortium Alliance Partnership Joint Venture Co-promotion and Marketing Licensing Equity Input 1. Collaboration models: B.Hughes, Nature Reviews Drug Discovery, 7, 631-2, 2008 Madhu Davies January 2018
Slide 15-

Context ‘Blockbusters’ up vs ‘patent cliff’ receding Stocks up, VC investment/IPO up Licensing down, Pharma investment lower (because prices relatively high…) Collaborations trendy Deals very complex/risk averse Patent life Opportunity cost/ time based competition Madhu Davies January 2018
Slide 16-

Patent Lifetime Issues Madhu Davies January 2018 Patent life set at 20 years from filing date (US) EU provides 8+2+1 years of exclusivity FDA will add time to this to recompense time under NDA review (Hatch Waxman act) Phase II and III trials can be long – end points, patient recruitment etc Regulatory burden increasing Countries not aligned to World Patent &Trademark Exchange Generic challenges before patent expiry Later filings – competitive risk WTP negotiations Line extension New business models that share risk Sales of a branded drug typically fall by >50% in the year following patent expiry (Bernstein and Co)
Slide 17-

Time based competition Madhu Davies January 2018 Trials Launch Peak sales Patent expiry Generic competition COST PROFIT Discovery TIME Pressure to speed up
Slide 18-

Discovery and early stage development planning Refer particularly to Introductory, Non-clinical and Clinical Pharmacology Sessions Madhu Davies January 2018
Slide 19-

The internal organisation of R&D Different companies have different structures- no right answer… Usually create a multidisciplinary project team Marketing and R&D and Manufacturing also represented One team with different leadership at different times in the cycle? Separate teams by function (discovery team hand on to development team hand onto commercial team)? Someone has to be in charge! Outsourcing This is normal regardless of company size Occurs at all levels in the process Madhu Davies January 2018
Slide 20-

What does it take to develop a drug? Madhu Davies January 2018
Slide 21-

Integrated drug development & commercialization capabilities Programme Strategy– to support clinical development and commercialization Medical Evidence Generation (RWE / HEOR) Market Access & Pricing Compliance / Safety reporting MSLs Patient supportprogrammes Regulatory Strategy & Submissions Market Research Clinical (TPP) Strategy QuantitativeMarket Forecast Evidence Analysis Brand Strategy AE reporting Pharmacovigilance Protocol design Medical Writing Operational Delivery Biometrics & Data Management Start-up & TMF Regulatory Affairs Strategy / Analytics Safety Management Clinical Operations Portfolio Management – Managing governance and delivery performance management Salesforce KAMs Field reimbursement managers Adherence solutions Field force support systems Advertising & PR Commercial Operations Medical Affairs Process, Therapeutic units, Advisory, Quality Assurance, Finance, HR, Legal, Contracting Based on an INC BD slide- with thanks
Slide 22-

Outsourcing: What does a CRO do? Exactly the same (R&D) processes as a pharma company- GXP Project management Discovery Toxicology Clinical Trials Clinical Labs Medical Consulting Medical Marketing Regulatory Affairs Drug safety/PV/ QA/ audit Pharmaceutical development of their own…. Contract Manufacturing (“CMO”) Etc., etc. Madhu Davies January 2018 Delegation NOT abdication!
Slide 23-

Managing investment and risk: Portfolio Management Madhu Davies January 2018 Value Probability of Success Cardiovascular Portfolio CNS Portfolio Size of shape represents resources required (FTE, $) for delivery Project decisions taken based on available resources and potential return – has to fit with company strategy G.E.Blau, J.F.Pekny, V.A.Varma, P.R.Bunch, J. Prod. Innov.Manag., 21, 227-245, 2004
Slide 24-

Portfolio management- hierarchy Madhu Davies January 2018
Slide 25-

Portfolio Management Product effects Assessment of future worth Probability of success Valuation of product revenue Estimation of project costs – resources and time Typically through a decision tree approach allowing the portfolio to be reassessed at key milestones. Real Option valuations can also be used a complex mathematical structure to estimate true project worth Variation in estimates is very high, making constant re-evaluation critical Group effects Conformance to strategic direction Numbers of options in development Madhu Davies January 2018
Slide 26-

What might we develop? Small molecules Biologicals Vaccines Devices Drug/device combinations Medicinal gases Cosmeceuticals (not a regulatory distinction) Life style drugs Foods and supplements Other? Madhu Davies January 2018 MoA? e.g. agonists, antagonists, enzyme inhibitors, functional (genomics and proteomics)
Slide 27-

Development planning Madhu Davies January 2018 Target Identification Lead Identification Lead Optimisation Development Medical Rationale Scientific Rationale Expected MOA ‘Nomination’ Discovery
Slide 28-

The goal? United States Prescribing Information Why? How? Madhu Davies January 2018
Slide 29-

DiscoveryRefer to Prof Gumbleton’s lecture Target identification Knowing what you are looking for e.g. a more selective LTB4 inhibitor Lead identification Combinational chemistry Substance Libraries High through-put screening Natural product screening Rational development Madhu Davies January 2018
Slide 30-

DiscoveryRefer to Prof Gumbleton’s lecture Lead optimisation The best of a series balancing issues such as: Synthetic route and simplicity / scalability Oral activity Duration of effect Receptor specificity Initial safety in animals Madhu Davies January 2018
Slide 31-

Nomination: Candidate Drug Profile (Builds to Target Product Profile) Madhu Davies January 2018
Slide 32-

Nomination: Candidate Drug Profile cont’d Madhu Davies January 2018 Development
Slide 33-

Phases of clinical development Phase 0: Used to rank drug candidates in order to decide which has the best pharmacokinetic parameters in humans to take forward into further development. No data on safety or efficacy, being by definition a dose too low to cause any therapeutic effect. Phase I: ~20-100 healthy volunteers/ patients with the disease; duration: ~months; Purpose: safety [dose]. ~70% of drugs move on to Phase II: Several hundred patients with disease; several months – 2 years; Purpose- efficacy and adverse effects. ~33% move on to Phase III: ~300-3000 patients with disease; 1-4 years; efficacy and monitoring of adverse effects. ~25% move on to the next phase Licensure Phase IV: Several thousand patients with disease; safety and efficacy; Madhu Davies January 2018
Slide 34-

Madhu Davies January 2018 Development planning
Slide 35-

Safety ToxicologyCross refer to Non clinical and Clinical Pharmacology Sessions Receptor binding information Impact on Respiratory rates and volumes Cardiovascular in vitro and in vivo QT interval tests Central nervous system behaviour, sensory / motor responses, body temp Gastrointestinal Bowel transit times Drug specific E.g. bone density for a cytokine Madhu Davies January 2018
Slide 36-

Endpoints- examples Madhu Davies January 2018
Slide 37-

End of ED assessment Posology E.g., once daily oral administration ADME / PK FIM Repeated Admin Proportionality Metabolite PK and activity Increased bioavailability vs competition? Interactions With drugs of concern or commonly used in target population Polymorphisms P450 CYP2D6 Enzyme induction Madhu Davies January 2018
Slide 38-

End of ED assessment cont’d Proof of Concept Human pharmacology (pain models, biomarkers) PD – dose predictions Range of doses that produce an effect and shape of curve Cmax and AUC at NOAEL in most sensitive species, not protein bound Animal toxicology- nature and severity Species comparative disposition Range of human doses expected to be needed Madhu Davies January 2018
Slide 39-

End of ED assessment cont’d Other drug specific features (must haves and must not haves) Not affected by food Not sedative Signal generation Evidence of developing side effect profile Commercial assessment Minimum acceptable profile compared to actual profile and viability assessed Madhu Davies January 2018
Slide 40-

Dose ranging The commonest error in development planning is the dose decision The move from phase II to III is the greatest cost increment in the lifecycle Running phase III studies at the wrong dose is a disaster in terms of direct and lost opportunity costs Phase II studies must not be timid... ...the trend is to undertake larger definitive studies, sooner Madhu Davies January 2018
Slide 41-

Discovery planning-summary Madhu Davies January 2018
Slide 42-

Madhu Davies January 2018
Slide 43-

Late stage (full) development Refer particularly to Clinical Trials, Regulatory, Pharmacovigilance, Statistics, Ethics/Legal/Health economics Sessions. Madhu Davies January 2018
Slide 44-

Discovery planning-summary Madhu Davies January 2018
Slide 45-

Phase III design list - pivotal to authorisation Objectives of study Is it safe? Is it effective? Allocation to therapies Statistical considerations Medically significant difference, power calculation Method of control of bias Choice of therapies Duration of therapies Patient population How are you going to reduce the variance? How are you going to ensure the study is close to real life? Madhu Davies January 2018
Slide 46-

Programme/project/product information R&D/ Senior Management Committees -internal [and external] Investigator Brochure Protocol and Informed Consent document Institutional Review Board/ Research Ethics Committee submissions Clinical Trial Applications Madhu Davies January 2018
Slide 47-

Medical Oversight of Clinical Trials Madhu Davies January 2018 Medical Monitoring Critical Event Committees Data and Safety Monitoring Board (DSMB)Medical Liaison Steering committee Clinical Trial
Slide 48-

End of Full Development - assessment Efficacy (hurdle 1) Does it work, compared to competitor or placebo. Superiority/non inferiority…Is it no worse (the same) or better? Safety (hurdle 2) Safety profile seen to date and risk benefit assessment? Signal generation Are other adverse effects emerging? Population Kinetics To supplement the core PK data- elderly, organ impaired, paediatrics etc Commercial Assessment-ongoing Target Product Profile vs Minimum Acceptable Profile vs actual profile, and commercial viability assessed. Landscape? Madhu Davies January 2018
Slide 49-

Some specific challenges of late phase development/studies “Before a new drug or biologic can be marketed, its sponsor must show, through adequate and well-controlled clinical studies, that it is effective” FDA CFR 314.126 Madhu Davies January 2018
Slide 50-

Some specific challenges of late phase development/studies Study design! Specific populations e.g. organ impaired/ timing of paediatric studies Leaky recruitment and retention in studies Availability of good principal investigators/sites Protocol complexity and subject numbers Patient demand vs site performance vs retention (again) Cost- e.g. just consider site start up costs: Starting up a site costs £25,000 - £75,000 Monitoring a site costs £2000 per month Missed visits cost on average £250 A drop out patient costs £20,000 (Source, MRN, 2015) Madhu Davies January 2018
Slide 51-

Potential solutions- work in progress Consider the needs and motivations of all stakeholders to develop better models of study execution and delivery e.g.: Patients Investigators Regulators Public Payers Investors Your company Madhu Davies January 2018
Slide 52-

Use insights gained to develop new study execution models If the rare resource is the patient, consider patient-centric approaches… For example, More thoughtful study design Virtual studies Community based trials Non-site based recruitment tools including social media Etc. Madhu Davies January 2018
Slide 53-

Madhu Davies January 2018
Slide 54-

Discovery planning-summary Madhu Davies January 2018
Slide 55-

Chemistry, Manufacturing, Pharmacy Drugs approved on the basis of Quality, Safety and Efficacy “Quality” is about the actual active substance Chemical structure Physical properties (appearance, solubility) Synthetic route Manufacturing process and controls Batch analysis Analytical procedures Stability Madhu Davies January 2018
Slide 56-

Chemistry, Manufacturing, Pharmacy cont’dSee Dr Smith’s lecture Formulation Description and formulation Manufacturing process and controls Control of excipients Analytical method Proof of structure Purity (identification impurities and amounts) Stability once formulated Certificate of analysis (includes assurance of adherence to GMP) Madhu Davies January 2018
Slide 57-

Commercial aspects of development stream Refer in particular to Medical Education and Promotion, Ethics/ Legal/ Health economics Sessions Madhu Davies January 2018
Slide 58-

Discovery planning-summary Madhu Davies January 2018
Slide 59-

Approval processes… Principally: New Drug Application (NDA) Biologics Licence Application (BLA) Marketing Authorisation Application (MAA) Madhu Davies January 2018
Slide 60-

Pre launch activities National Payer/Purchaser adoption - The “4th hurdle” Quality of life Health Economics Place in the treatment algorithm Patent positions by country Pricing negotiations by country Final commercial assessment on country- by-country basis Launch planning Post launch obligations and PV requirements Madhu Davies January 2018
Slide 61-

Where do things go wrong? CRITICAL challenges are: Portfolio choices – pick the winners Dose –must get this right but often don’t Target- right disease Recognising the clues BUT– if it can go wrong, it probably will Plan with the end in mind Don’t draw conclusions that are not supported by the data Follow Quality Methodologies – prevent rework Be very precise about the science Regulatory dialogue If you find yourself in conversations about regulations, make sure you know them. Madhu Davies January 2018
Slide 62-

Expanded access Once a product is in phase III Waiting for license review and approval Patients may wish / benefit from continuing on their trial medication Issues arise with blinding if not designed into the study from the start Many ECs require patients to be offered the new medication at the end of the trial Often delivered as open label trial extension Not ‘named patient’ Madhu Davies January 2018
Slide 63-

Product Launch Once the license is granted, the product may then be officially launched (NB Pricing and reimbursement) All the dossier data with marketing value is published, most phase II and III data is released peri launch The sales team needs education and training Corporate and local affiliate medical, marketing regulatory and other departments need education and training Companies create a major presence at conferences Corporate and local roll out of global commercial platform messaging i.e. promotional campaign needs to be created and approved Madhu Davies January 2018
Slide 64-

Product Launch Branding is initiated Purchasing groups are targeted Pricing negotiations commence Manufacturing and supply chains must be operational Professional bodies are targeted - associations of specialists, patient pressure groups, opinion leaders and prescribing leaders Madhu Davies January 2018
Slide 65-

Post launch trials Conditions of approval may include: Post authorization safety studies Post authorization efficacy studies Expansion of knowledge of product by various types of study New indications New data is required soon to maintain ‘noise’ All new medicines undergo a huge increase in patient exposure, with safety implications Many aspects of the product are unconfirmed or unknown at launch - MOA, pharmacology, QoL, Health Economics, maturing AE profile Madhu Davies January 2018
Slide 66-

PharmacovigilanceRefer to Pharmacovigilance Session Requirements Regulatory Marketing PSURs Yellow card systems Registries Post Authorisation Safety Studies Getting a denominator Sales figures IMS DSRU Madhu Davies January 2018
Slide 67-

Madhu Davies January 2018
Slide 68-

Lifecycle management-Evergreening Keeping the product patent protected Developing new indications and formulations Delayed release formulations Gels, creams, i.v., epidural etc Combination therapies Expanding indications e.g. Types of arrhythmias Types of pain Types of infection Prophylactic use New algorithms Madhu Davies January 2018
Slide 69-

Structure of the SmPC Information is presented according to a predefined structure Certain information is suitable in different sections but cross-references are made to avoid repetitive information Madhu Davies January 2018
Slide 70-

Madhu Davies January 2018
Slide 71-

Madhu Davies January 2018